Pharsight

Zypitamag generic

Zypitamag is an FDA-approved drug owned by Medicure. Its active ingredient is pitavastatin magnesium. The drug was first granted market authorization in the United States on 14 July, 2017.

When will Zypitamag generic be available?

The last patent held by Zypitamag is expected to expire on 19 January, 2031. This might pave the way for generic versions of the drug to become available for the public.

Zypitamag uses

Zypitamag, containing pitavastatin magnesium, is commonly used for managing high cholesterol and triglycerides. It is available in a tablet form for oral administration.

Zypitamag patent expiration

The drug Zypitamag holds a total of 1 drug patent, none of which have expired. The patent with title 'Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof' is expected to expire last, on the 19th of January, 2031. When patents for the brand-name drug expire, Zypitamag generic could potentially be available. Below are the details of the patent:

Zypitamag dosage

Want to ask something?